Danaher's Takeover-Minded Owner Now Can't Make A Deal

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Danaher Corp. (DHR) investors are antsy for the industrial conglomerate to make a big acquisition.

The company hasn’t done a deal of at least $500 million since 2012, its longest drought in 11 years, according to data compiled by Bloomberg. That’s contributed to the worst start to a year since 2008 for Danaher stock, as annual sales also expanded at the slowest pace since 2009. Investors are holding off on buying Danaher shares until the $56 billion company, known for its dealmaking, gets back in the game with a transaction big enough to spark some growth, said Longbow Research.

Hey, check out all the research scientist jobs. Post your resume today!

Back to news